
Roadside Real Estate plc
("Roadside" or the "Company")
Update on Cambridge Sleep Sciences
Clinical trial results
Appointment of new chief executive officer
Roadside (AIM: ROAD) provides the following update on its 47.8% investment holding in Cambridge Sleep Sciences ("CSS").
New clinical trial results released
CSS is pleased to announce the results of a second clinical trial of its SleepEngineTM technology, demonstrating its effectiveness in helping to improve the quality of adult sleep. The trial, led by Dr. Nigel Guest, showed that all participants using SleepEngineTM technology reported an improvement in their sleep quality.
The trial consisted of 19 adult participants with self-reported insomnia lasting over six months, who used a SleepHub® device featuring the SleepEngineTM technology for a period of 12 weeks. Their sleep quality was measured using a sleep diary and the globally respected Pittsburgh Sleep Quality Index, ("PQSI") rating scale ranging from 0 - 21, where higher scores indicate poorer sleep quality and a change of three points is considered significant.
From a baseline score of 11.21, the PSQI decreased by a statistically and clinically significant level of 4.21 (p<0.001) to a score of 7, indicating a substantial impact on sleep quality, taking trial participants from the moderate to the mild sleep difficulty range. During the eight-week washout phase, where the technology was no longer being used, its impact was still experienced with the PSQI score decreasing further by 1.28 (p<0.012) to 5.72.
The latest trial results support the first unpublished trial of SleepEngineTM from 2016, where 92% of participants experienced an improvement in their sleep quality and an average increase in time asleep of 155 minutes. The latest trial results also reflect the anecdotal feedback received from users of the SleepHub® device over the last four years.
Appointment of new chief executive officer of CSS
CSS has appointed Adam Rostom as its chief executive officer with a mandate to accelerate CSS's commercial growth, seizing global licensing opportunities and expanding its presence in the bedding and wellness markets. His leadership will also drive the development of next-generation sleep solutions, working with health tracking brands to integrate continuous biomarker tracking with real-time sleep interventions.
Mr. Rostom has helped scale the businesses of household names including Innocent Drinks, Dyson, OVO Energy, Babylon Health and Many Pets. As a PhD biochemist with a passion for business, he has helped build and transform a number of high-growth businesses, blending creativity with commercial impact.
Former chief executive officer of CSS, Julian Stone, has been appointed President of the company, focusing on developing existing and new business globally.
CSS expects to issue a trading update on or around 28 February, 2025.
Charles Dickson, Executive Chairman of Roadside, said:
"This statistically significant trial proves our belief in CSS's technology as it continues to successfully help users improve their quality to sleep. We're excited by the diverse range of licensing opportunities the business is developing to find innovative new applications for its technology. I believe Adam and Julian will form a formidable combination to deliver the next chapter of CSS's story."
- Ends -
For more information
Roadside Real Estate plc Charles Dickson, Executive Chairman c/o Montfort
| |
Cavendish Capital Markets Limited (Nomad and Joint Corporate Broker) Carl Holmes / Seamus Fricker (Corporate Finance) Tim Redfern / Jamie Anderson (ECM)
|
+44 (0)20 7220 0500 |
Stifel Nicolaus Europe Limited (Financial Adviser and Joint Corporate Broker) Mark Young Jonathan Wilkes-Green Catriona Neville
| +44 (0)20 7710 7600 |
Montfort Olly Scott Bella Leathley |
+44 (0)78 1234 5205 +44 (0)74 7168 7266 |
About Roadside
Roadside is a real estate business focused on building and scaling a high-quality portfolio of modern roadside retail assets, including modern EV charging infrastructure.
About Cambridge Sleep Sciences Ltd
Cambridge Sleep Sciences Ltd, is a legacy Life Sciences investment in which Roadside Real Estate plc holds a 47.8% interest. CSS develops technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, its innovative solutions aim to improve health, wellbeing and enhance quality of life.
Its SleepEngineTM technology has been developed and refined over fifteen years by a team of researchers, scientists, sound engineers and medical experts. This unique technology produces sounds which emulate the waves created by the brain during sleep cycles. The sleep sounds guide the user's brain through the sequence of healthy sleep cycles, helping them fall asleep and achieve the quality of sleep they need in a consistent and optimal way.
Find out more at: www.cambridgesleepsciences.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.